Matching Portfolios

by David Kane and Jeff Enos June 18, 2006

1 Introduction

"Matching" portfolios is a technique for generating a reasonable benchmark for determining the relative performance of a specific equity portfolio and is based on the work in Ho et al. (2005a). Consider the simplest case of a long-only mutual fund that has returned 10% in the last year. Has the portfolio done well? If the average stock in the universe has gone up 50% then, obviously, the portfolio has done poorly. If, on the other hand, the average stock has gone down 25%, then the portfolio has done remarkably well. In other words, it is impossible to evaluate the performance of a portfolio without considering the hypothetical performance of other possible portfolios. In this case, we are comparing the performance of our portfolio to that of a hypothetical portfolio that is equal-weighted all the stocks in the universe. But, depending on the characteristics of our mutual fund, this may not be a reasonable benchmark. More information on the performance measurement problem and possible solutions can be found in Burns (2004).

Matching portfolios provide a benchmark which matches the characteristics—sector exposures, capitalization biases, position sizes—of the target portfolio. The portfolio package provides the matching method as a means of computing a matching portfolio. In this article we describe the intuition behind matching in general, frame a real-world problem in which computing a portfolio benchmark is difficult, and show how the matching facility of the portfolio package can be used to solve this problem.

2 Data

To focus ideas, let's examine a specific portfolio formed on December 31, 2004. Assay Research¹ is a forensic accounting that provides "in-depth insight into financial statements, accounting practices and policies, and quality-of-earnings of publicly-traded companies." Assay maintains a "Focus List" of companies for which its concerns are "heightened." Although Assay does not provide buy/sell recommendations, most if its customers would expect the stocks on its Focus List to perform poorly going forward.

 $^{^{1} {\}it www.assayresearch.com}$

On December 31, 2004, there were 33 companies on Assay's Focus List. The list of companies, along with data on a total of 4,000 stocks that were trading at that time, are available as part of the R "portfolio" package.

> library(portfolio)

```
Loading required package: grid
Loading required package: lattice
```

- > data(assay)
- > assay[c(1, 10, 100, 1000, 3000, 767),]

	id	symbol		name	country	currency	price	sector
22101	36960410	GE	GENERAL E	LECTRIC CO	USA	USD	36	${\tt Industrials}$
29780	47816010	JNJ	JOHNSON	& JOHNSON	USA	USD	63	Staples
17157	26054310	DOW	DO'	W CHEMICAL	USA	USD	50	Materials
57743	663710	NCM.AU	NEWCREST 1	MINING LTD	AUS	AUD	17	Materials
52459	646862	8584	JA	CCS CO LTD	JPN	JPY	616	Financials
6930	G3726010	GRMN		GARMIN LTD	USA	USD	61	Technology
	liquidity	assay	ret.0.3.m	ret.0.6.m				
22101	2.84	FALSE	-0.0059	-0.021				
29780	2.42	FALSE	0.0635	0.078				
17157	1.90	FALSE	0.0137	-0.089				
57743	0.74	FALSE	-0.0023	-0.115				
52459	-0.47	' FALSE	0.2138	0.142				
6930	1.63	TRUE	-0.2387	-0.297				

The variables in the data frame are as follows.

- id is an identifier for each security, generally a CUSIP for companies traded on US exchanges and a SEDOL for companies traded elsewhere.
- symbol is a human-readable identifier that is generally the ticker that the security trades under in its home market; exchange specific information is sometime appended to it. For example, Newcrest Mining trades under the ticker "NCM" in Australia, indicated by the "AU" suffix.
- name is the name of the company. We will generally use the terms "company" and "security" interchangeably even though a "company" is a single legal entity which often has several different types of securities associated with it. In this example, we are only examining the single primary equity security for each company.
- country is the ISO code for the country in which the security is traded. Note that this is not necessarily the same as the country in which the company is headquartered or incorporated. For example, Garmin (GRMN) is trades in the US but is incorporated in the Cayman Islands.²
- currency is the ISO code for the currency in which the security trades.

²http://www.garmin.com

- price is the latest closing price for the security as of December 31, 2004. (Not all securities traded on that date.)
- sector is the economic sector in which a majority of the company's business takes place. There are 10 sectors in this data including Communications, Cyclicals, Energy, Financials and Technology.
- liquidity is a measure of the typical daily dollar volume of trading in the security. We normalized it to be N(0,1)..
- assay is a TRUE/FALSE indicator of whether or not the security was on the Assay Focus List on December 31, 2004. Thirty three companies were on the list at that time.
- ret.0.3.m and ret.0.6.m are the three and six month, respectively, returns for each security, including dividends.

There are no missing observations. The universe of 4,000 companies was constructed by including the all the stocks on the Assay Focus list along with other large companies. The universe is restricted to companies that trade on exchanges in developed markets. For example, we include Japan but not South Korea, Austria but not Croatia.

3 An Assay Focus List (AFL) Portfolio

Consider a portfolio formed by taking equal-weighted short positions in each of the Assay Focus List stocks and focusing in the returns for the first three months, through March 31, 2005.

```
> assay$assay.wt <- ifelse(assay$assay, -1, NA)</pre>
> p <- new("portfolioBasic", data = assay, id.var = "symbol", in.var = "assay.wt",
      type = "relative", size = "all", ret.var = "ret.0.3.m")
An object of class "portfolioBasic" with 33 positions
Selected slots:
name: Unnamed portfolio
date: 2006-06-18
in.var: assay.wt
ret.var: ret.0.3.m
type: relative
size: all
> summary(p)
Portfolio: Unnamed portfolio
        count
                    weight
Long:
            0
                         0
```

```
Short:
           33
                         -1
Top/bottom positions by weight:
     id pct
  ACXM
        -3
1
2
   AFFX
         -3
3
   ANSI
   ARTC
4
         -3
5
     ΑV
         -3
29
    SLE
         -3
   UNA
30
         -3
31 USPI
         -3
32 UTSI
         -3
   VCI
> summary(performance(p))
Total return: 7.64 %
Best/Worst performers:
     id weight
                 ret contrib
18 HOTT -0.030 0.27 -0.0082
21 KOMG -0.030 0.19 -0.0058
  AFFX -0.030 0.17 -0.0052
26 PDCO -0.030
               0.15 -0.0046
12 ELAB -0.030 0.12 -0.0036
24 OPWV -0.030 -0.21
                      0.0064
17 GRMN -0.030 -0.24
                      0.0072
   ANSI -0.030 -0.32
5
     AV -0.030 -0.32
                      0.0097
```

32 UTSI -0.030 -0.51

This portfolio returns 7.64% because the average Assay stock fell in price by this amount during the first quarter of 2005. Now, making 7% in three months is rarely a bad thing, but whether or not this counts as good performance depends on what the other stocks in the universe did during this time period. After all, instead of paying for access to Assay's Focus List (AFL), we could have just selected 33 stocks randomly and shorted them.

0.0153

Since the average stock in our universe of $4{,}000$ was up 1.4%, the performance of the AFL portfolio appears quite good. If we consider a reasonable benchmark to be shorting 33 randomly selected stocks from the universe, then the AFL portfolio would have outperformed by 9%.

But is the Assay portfolio similar to the rest of the universe? To some extent, it is. All the securities in the universe are relatively larger capitalization, liquid equities traded on developed market stock exchanges. But the AFL portfolio is also very different since all of its components are US stocks. Is it fair to use a benchmark with international stocks as a comparison for a US-only portfolio like APL? Probably not.

Another major difference between the AFL portfolio and the universe is that the AFL is concentrated in a limited number of sectors.

```
> exposure(p, exp.var = "sector")
sector
        variable long short exposure
                     0 -0.091
                                 -0.091
1 Communications
     Industrials
                     0 -0.091
                                 -0.091
3
2
       Cyclicals
                     0 -0.121
                                 -0.121
4
         Staples
                     0 -0.303
                                 -0.303
5
      Technology
                     0 -0.394
                                 -0.394
```

The analysts at Assay do not place companies from sectors like Financials, Energy and Utilities on to their Focus List because they lack the industry knowledge to evaluate the financial statements for such companies. Any benchmark which includes securities from such sectors is inappropriate for judging the skill of Assay. After all, if Energy stocks did very well in the first quarter of 2005, a benchmark short portfolio which included them would do very poorly. Assay would hardly deserve "credit" for this since it is not claiming that stocks in sectors which it does not cover will do well. It makes no predictions about how energy stocks, on average, will do.³

Even if we were to eliminate non-US stocks from the universe and stocks in sectors that Assay does not cover, we would still be left with a variety of incompatibilities between the AFL portfolio and possible benchmarks. For example, the average Assay stock has a liquidity of over 0.5, more than 1/2 a standard deviation greater than the universe as a whole. The Assay portfolio has almost 40% of its holdings in Technology stocks. The universe as a whole is only 7% Technology. What we need is a benchmark portfolio that looks like, that "matches," the Assay portfolio in terms of variables like country, sector, liquidity and so on but which is otherwise randomly selected from non-Assay stocks in the universe.

4 A Matching Portfolio

The solution to the problem of constructing a benchmark for a portfolio like that derived from the Assay Focus List is to create a "matching" portfolio, a portfolio that is as similar in its characteristics as the target portfolio as possible without being identical to it. For the AFL benchmark, we would like a portfolio with similar country and sector breakdown as well as a similar distribution of liquidity. If the AFL portfolio does much better (because the Assay stocks do very poorly) than this benchmark, we have evidence that Assay has in fact identified companies with significant problems. It isn't just a matter of the AFL doing well relative to the overall universe because, for example, Energy stocks have risen so much and the AFL isn't short any energy stocks.

 $^{^3{\}rm Energy}$ was, in fact, the best performing sector in Q1 2005, with the average stock up over 15%.

4.1 Statistical Intuition

One way to think about the assessment of the AFL is to consider an analogy to a randomized scientific experiment. Recall that a randomized experiment or trial begins by selecting a group of subjects to work with. From this population, a group of subjects is randomly selected and to whom is applied the treatment. The rest of the group receives the control. Since the treatment was applied randomly, any differences in the outcome should be the result of the treatment rather than be caused by systematic differences between the treatment and control groups (Rubin (1974)).

Consider a group of 4000 individuals with a headache. We want to determine if the treatment of "taking an aspirin" relieves the headache better than the control of "taking a placebo." If we only have, say, 33 aspirins to use for the test, we should select 33 people at random from the group of 4000 and give them each an aspirin. The other individuals get the placebo. Afterward, we can see how the treatment group (having taken the aspirin) compares to the control group (who took the placebo). If, for example, the reported headache pain of the treated group is much lower than that of the control group, we might conclude that aspirin works.

Imagine that we have a "treatment" which we believe causes stock prices to fall. We want to test to see if this treatment actually has that effect. The best way to do so is to run a randomized trial. Select, say, 33 stocks at random from the total universe of 4,000 stocks. Apply the treatment to those 33 stocks but not to the other 3,967. If the price of the 33 treated stocks falls more (or rises less) then the prices of the 3,967 control stocks, we might conclude that the treatment works.

The problem arises, for both tests of aspirin and tests of Assay, when we can no longer do random assignment. Imagine that, instead of assigning aspirin/placebo randomly, 33 of the 4,000 people in our group volunteer to take it. The problem is that these 33 might be very different from the others. They might be all men or mostly old or very fat. Unless we somehow "control" for this problem, we will not be able to conclude that the treatment, the aspirin, actually caused the decrease in headache pain. Instead, it could just be that headaches go away more quickly in old, fat men. Instead of comparing our 33 volunteers to everyone else, we need to compare them to a subgroup that "matches" them. If they are mostly male, old and fat, we should select a control group of people who took the placebo that is equally male, old and fat. If aspirin-takers report less pain in this group, then we might reasonably conclude that — at least within this subpart of the population — aspirin works.

The same intuition lies behind the construction of a matching portfolio. We need a portfolio that looks like the AFL portfolio in terms of country, sector and liquidity. If the only difference between the AFL and matching portfolio is that the former consists of stocks that Assay has "heightened" concerns about while the latter consists of similar stocks without such concerns, we may conclude that any differences in their subsequent performance is due to the treatment received. Now, of course, placement on the Focus List does not *cause* a stock

decline in the same way that taking an aspirin causes, by hypothesis, headache pain to decrease. But, mathematically, the set up is the same.

4.2 Making a Match

We want a matching portfolio which is as similar as possible to the Assay Focus List portfolio but which does not include the same stocks. The matching method in the portfolio package provides this functionality, with a little help from the MatchIt package (Ho et al. (2005b)). Calling this method on a portfolio object p returns a portfolio with none of the same positions as p but whose positions most closely resemble those in p along the dimensions specified in the covariates argument:

```
> p.m <- matching(p, covariates = c("country", "sector", "liquidity"))
> summary(p.m)
Portfolio: Unnamed portfolio
                    weight
        count
            0
Long:
                         0
Short:
           33
                        -1
Top/bottom positions by weight:
     id pct
   ABGX -3.03
  ALTR -3.03
   AVID -3.03
     BE -3.03
    BOL -3.03
29 TSRA -3.03
30 TTWO -3.03
31 USTR -3.03
32 WCG -3.03
   YCC -3.03
33
```

A quick inspection of the new portfolio's positions confirms that none of the positions of p.m appear in p.

```
> all(!p.m@weights$id %in% p@weights$id)
```

[1] TRUE

Having created a matching portfolio using country, sector, and liquidity as covariates, we would expect p.m and p to have similar exposures to these variables. First, all of the positions in p.m have country USA. This makes sense because all AFL stocks, and thus all stocks in p, are US stocks. More interestingly, however, the sector exposures of p.m are quite similar to the sector exposures of p:

```
> exposure(p.m, exp.var = "sector")
sector
        variable long
                         short exposure
1 Communications
                    0 -0.06061 -0.06061
       Cyclicals
2
                    0 -0.09091 -0.09091
3
     Industrials
                    0 -0.12121 -0.12121
4
         Staples
                    0 -0.33333 -0.33333
5
      Technology
                    0 -0.39394 -0.39394
```

The only difference sector-wise between the two portfolios is that p.m has one more stock in Staples and one less stock in Communications. Finally, the exposure of p to the numeric variable liquidity:

```
> exposure(p, exp.var = "liquidity")
numeric
   variable long short exposure
1 liquidity   0 -0.541   -0.541
   is quite close to p.m's exposure to liquidity:
> exposure(p.m, exp.var = "liquidity")
numeric
   variable long short exposure
1 liquidity   0 -0.4894   -0.4894
```

Since we matched using more than one covariate, we shouldn't expect the matching portfolio's exposures to the covariates to be exactly the same as those of the original portfolio. However, given a large enough universe upon which the matching method can draw, we expect those exposures to be reasonably close.

4.3 The Match as a Benchmark

Now that we've run matching on our AFL portfolio and calculated a match, we can examine how the AFL portfolio performed relative to the match. Recall that the AFL portfolio returned 7.64% during Q1 2005, and that members of our 4000 stock universe were up 1.4% on average during this period. The AFL portfolio, then, outperformed a randomly selected portfolio of 33 stocks from our universe by 9%.

The match, however, performed far better than a randomly selected portfolio:

```
> summary(performance(p.m))
Total return: 4.78 %
Best/Worst performers:
   id weight ret contrib
```

```
7 CMTL -0.03030 0.3853 -0.011675
29 TSRA -0.03030 0.1618 -0.004903
5 BOL -0.03030 0.1392 -0.004219
30 TTWO -0.03030 0.1239 -0.003754
10 ELX -0.03030 0.1188 -0.003599
9 ECLP -0.03030 -0.2423 0.007342
14 IMCL -0.03030 -0.2513 0.007615
19 MTSN -0.03030 -0.2917 0.008840
1 ABGX -0.03030 -0.3230 0.009788
17 LVLT -0.03030 -0.3923 0.011889
```

The match returned 4.78% during Q1 2005, a far better return than the -1.4% of a randomly selected portfolio. If we then use the matching portfolio as the AFL portfolio's benchmark, the AFL portfolio had an excess return of 2.86%. While this excess return is lower than the 9% we would calculate using a randomly selected benchmark, it more accurately reflects the excess return for which Assay should receive "credit".

For example, while the average stock in our universe returned 1.4%, the average US stock returned -3.6%. We could have simply shorted a random collection of 33 US stocks and walked away with 3.6%. Futhermore, stocks in the Technology and Staples sectors on average returned -4.7% and -4.5%, respectively. The matching portfolio, like the AFL portfolio, benefits from having over two-thirds of its positions in these sectors. Finally, stocks with liquidity values close to 0.5, the average liquidity value of AFL stocks, have the same or slightly poorer returns than the average stock in the universe. The AFL portfolio does not perform better or worse than a random portfolio due to its exposure to higher liquidity stocks.

It is clear that the matching portfolio is a better benchmark for the AFL portfolio than a randomly selected portfolio, particularly due to the poor average return of US stocks and stocks in the Technology and Staples sectors relative to the entire universe.

References

Patrick Burns. Performance measurement via random portfolios, 2004. URL http://www.burns-stat.com/pages/Working/perfmeasrandport.pdf.

Daniel Ho, Kosuke Imai, Gary King, and Elizabeth Stuart. Matching as nonparametric preprocessing for parametric causal inference, 2005a. URL http://gking.harvard.edu/files/matchp.pdf.

Daniel Ho, Kosuke Imai, Gary King, and Elizabeth Stuart. *MatchIt: Non-parametric Preprocessing for Parametric Casual Inference*, 2005b. URL http://gking.harvard.edu/matchit. R package version 2.2-5.

Donald B. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of Educational Psychology*, 66:688–701, 1974.